Trademark: 87398429
Word
FOREVHER
Status
Registered
Status Code
700
Status Date
Tuesday, May 7, 2019
Serial Number
87398429
Registration Number
5746161
Registration Date
Tuesday, May 7, 2019
Mark Type
4000
Filing Date
Tuesday, April 4, 2017
Published for Opposition
Tuesday, January 9, 2018

Trademark Owner History
TherapeuticsMD, Inc. - Original Registrant

Classifications
44 Providing medical information to patients in the field of relief of perimenopausal and menopausal symptoms with FDA approved treatment options to further patient care in the field of women's health
FOREVER

Trademark Events
Feb 1, 2023
Assignment Of Ownership Not Updated Automatically
Jan 30, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 30, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 7, 2019
Registered-Principal Register
Apr 2, 2019
Notice Of Acceptance Of Statement Of Use E-Mailed
Apr 1, 2019
Allowed Principal Register - Sou Accepted
Mar 7, 2019
Statement Of Use Processing Complete
Feb 14, 2019
Use Amendment Filed
Mar 7, 2019
Case Assigned To Intent To Use Paralegal
Feb 14, 2019
Teas Statement Of Use Received
Aug 15, 2018
Notice Of Approval Of Extension Request E-Mailed
Aug 13, 2018
Sou Extension 1 Granted
Aug 13, 2018
Sou Extension 1 Filed
Aug 13, 2018
Teas Extension Received
Mar 6, 2018
Noa E-Mailed - Sou Required From Applicant
Jan 9, 2018
Official Gazette Publication Confirmation E-Mailed
Jan 9, 2018
Published For Opposition
Dec 20, 2017
Notification Of Notice Of Publication E-Mailed
Dec 3, 2017
Assigned To Lie
Nov 22, 2017
Approved For Pub - Principal Register
Nov 21, 2017
Teas/Email Correspondence Entered
Nov 20, 2017
Correspondence Received In Law Office
Nov 20, 2017
Teas Response To Office Action Received
May 18, 2017
Notification Of Non-Final Action E-Mailed
May 18, 2017
Non-Final Action E-Mailed
May 18, 2017
Non-Final Action Written
May 2, 2017
Assigned To Examiner
Apr 11, 2017
Notice Of Pseudo Mark E-Mailed
Apr 10, 2017
New Application Office Supplied Data Entered
Apr 7, 2017
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24